TITLE

Nventa reports positive results from Phase I cervical dysplasia trial

PUB. DATE
September 2008
SOURCE
PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p11
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the result of the drug study conducted by Nventa Biopharmaceuticals Corp. which assesses the effectiveness of its HspE7 drug for treating cervical intraepithelial neoplasia (CIN) patients. The study focused on evaluating the drug's response and immunogenecity to different doses of the adjuvant Poly-ICLC, which are 50, 500, 1000 and 2,000 milligrams. It reveals that the drug showed positive performnace and enhanced HPV16 E7-specific T-cell respones.
ACCESSION #
34382735

 

Related Articles

  • Crohn's Disease: MMF Not the Cure-All for 6-MP/AZA Treatment Failures. Young, R. L.; Thompson, Jon S. // American Journal of Gastroenterology;Jul2000, Vol. 95 Issue 7, p1626 

    Discusses research being done on the efficacy of mycophenolate mofetil (MMF) in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Reference to a study by L. Kam and colleagues published in a 2000 issue of "Inflammatory Bowel Disease" journal; Clinical information on...

  • Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with... Meyskens Jr., Frank L.; Surwit, Earl // JNCI: Journal of the National Cancer Institute;4/6/94, Vol. 86 Issue 7, p539 

    Presents the results of a randomized phase III trial to determine whether topically applied retinoic acid reversed moderate cervical intraepithelial neoplasia (CIN) II or severe CIN. Patient eligibility; Histological classification of dysplasia; Biopsy-cytology evaluation; Therapeutic regimen;...

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Oct2007, Vol. 6 Issue 10, p8 

    The article reports that Nventa Biopharmaceuticals Corp. has started a Phase I trial which evaluates the safeness and tolerability of its therapeutic vaccine in patients with cervical intraepithelial neoplasia (CIN) in the U.S. It also aims to assess T-cell and B-cell specific HPV-E7 immune...

  • CLINIC ROUNDUP.  // BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2 

    This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim...

  • Research Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug...

  • NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL.  // Worldwide Biotech;May2008, Vol. 20 Issue 5, p1 

    The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It...

  • The Effectiveness of Topical Pimecrolimus in the Treatment of Oral Lichen Planus. Mülayim, Mehmet Kamil; Öztürk, Perihan; Uzun, Soner // Turkish Journal of Dermatology / Turk Dermatoloji Dergisis;2016, Vol. 10 Issue 4, p152 

    Objectives: Oral lichen planus (OLP) is a chronic inflammatory disorder of unknown etiology that affects the skin and the mucosa, especially the oral mucosa. Several therapeutic agents have been investigated for the treatment of OLP. All agents used in the OLP therapy are palliative. Potent...

  • Cervical dysplasia regression induced by all-trans-retinoic acid. Sporn, Michael B.; Roberts, Anita B. // JNCI: Journal of the National Cancer Institute;4/6/94, Vol. 86 Issue 7, p476 

    Editorial. Comments on F.L. Meyskens et al's report in the April 6, 1994 issue of the `Journal of the National Cancer Institute,' on how topical application of all-trans-retinoic acid (RA) can enhance regression of dysplasia of the uterine cervix. Basis for the conclusion; Significance of the...

  • Phase II/III.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p16 

    Provides information related to latest phase II/III clinical trials. Initiation of a trial for an inhalable form of treprostinil for pulmonary hypertension by Lung Rx; Efficacy of Fibrillex at improving symptoms of Amylois A Amyloidosis, based on Neurochem Inc.'s trial.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics